SC 13G/A | 2024-02-14 | VIKING GLOBAL INVESTORS LP | Adaptive Biotechnologies Corp | 29,993,708 | 20.7% | EDGAR |
SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Adaptive Biotechnologies Corp | 12,767,684 | 8.8% | EDGAR |
SC 13G/A | 2024-01-29 | ARK Investment Management LLC | Adaptive Biotechnologies Corp | 12,806,513 | 8.8% | EDGAR |
SC 13G | 2024-01-26 | BlackRock Inc. | Adaptive Biotechnologies Corp | 11,421,554 | 7.9% | EDGAR |
SC 13G | 2023-02-13 | BlackRock Inc. | Adaptive Biotechnologies Corp | 12,374,197 | 8.7% | EDGAR |
SC 13G | 2023-02-10 | ARK Investment Management LLC | Adaptive Biotechnologies Corp | 9,201,245 | 6.4% | EDGAR |
SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Adaptive Biotechnologies Corp | 11,794,168 | 8.2% | EDGAR |
SC 13G/A | 2022-09-12 | PRICE T ROWE ASSOCIATES INC /MD/ | Adaptive Biotechnologies Corp | 4,081,518 | 2.9% | EDGAR |
SC 13G/A | 2022-02-14 | Matrix Capital Management Company, LP | Adaptive Biotechnologies Corp | 11,572,590 | 8.2% | EDGAR |
SC 13G/A | 2022-02-14 | VIKING GLOBAL INVESTORS LP | Adaptive Biotechnologies Corp | 29,993,708 | 21.3% | EDGAR |
SC 13G/A | 2022-02-10 | PRICE T ROWE ASSOCIATES INC /MD/ | Adaptive Biotechnologies Corp | 14,240,614 | 10.0% | EDGAR |
SC 13G | 2022-02-10 | PRICE T ROWE ASSOCIATES INC /MD/ | Adaptive Biotechnologies Corp | 13,286,713 | 9.4% | EDGAR |
SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | Adaptive Biotechnologies Corp | 11,031,288 | 7.8% | EDGAR |
SC 13G/A | 2021-02-16 | Matrix Capital Management Company, LP | Adaptive Biotechnologies Corp | 13,115,090 | 9.6% | EDGAR |
SC 13G/A | 2021-02-16 | VIKING GLOBAL INVESTORS LP | Adaptive Biotechnologies Corp | 29,993,708 | 21.9% | EDGAR |
SC 13G | 2021-02-10 | VANGUARD GROUP INC | Adaptive Biotechnologies Corp | 9,655,425 | 7.1% | EDGAR |
SC 13G | 2020-02-14 | Matrix Capital Management Company, LP | Adaptive Biotechnologies Corp | 17,332,191 | 13.9% | EDGAR |
SC 13G | 2020-02-11 | VIKING GLOBAL INVESTORS LP | Adaptive Biotechnologies Corp | 38,406,607 | 30.9% | EDGAR |